Tyrvaya - (0.03 mg/ spray; Nasal Spray)

Generic Name	Varenicline Tartrate	Innovator	Oyster Point Pharma
Dosage	0.03 mg/ spray; Nasal Spray	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	TYRVAYA (varenicline solution) nasal spray is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******	*** / *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events